DBV Technologies (DBVT) Operating Income (2014 - 2026)
DBV Technologies (DBVT) reported Operating Income of -$47.9 million for Q1 2026, down 80.08% year-over-year from -$240.4 million in Q1 2025, and down 6.32% on a QoQ basis from -$45.1 million in Q4 2025.
DBV Technologies (DBVT) has 12 years of Operating Income data on file, last reported at -$47.9 million in Q1 2026.
- Quarterly Operating Income fell 80.08% year-over-year to -$47.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$168.3 million (down 46.85% YoY) and the FY2025 annual result came in at -$147.1 million, down 26.13% from the prior year.
- Operating Income retreated to -$47.9 million in Q1 2026 per DBVT's latest filing, from -$45.1 million in the prior quarter.
- Across five years, Operating Income topped out at -$11.9 million in Q4 2023 and bottomed at -$47.9 million in Q1 2026.
- The 5-year median for Operating Income is -$26.6 million (2025), against an average of -$28.5 million.
- The widest annual swing landed in 2022, when Operating Income plunged 182.09%; it then jumped 68.65% in 2023.
- Tracing DBVT's Operating Income over 5 years: stood at -$38.0 million in 2022, then surged by 68.65% to -$11.9 million in 2023, then sank by 100.18% to -$23.9 million in 2024, then tumbled by 88.81% to -$45.1 million in 2025, then dropped by 6.32% to -$47.9 million in 2026.
- Per Business Quant, the three latest DBVT Operating Income figures stand at -$47.9 million (Q1 2026), -$45.1 million (Q4 2025), and -$34.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | -47.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.90 Mn |
| Dec 31, 2025 | -45.05 Mn |
| Sep 30, 2025 | -34.28 Mn |
| Jun 30, 2025 | -41.11 Mn |
| Mar 31, 2025 | -26.60 Mn |
| Dec 31, 2024 | -23.86 Mn |
| Sep 30, 2024 | -30.33 Mn |
| Jun 30, 2024 | -33.84 Mn |
| Mar 31, 2024 | -28.56 Mn |
| Dec 31, 2023 | -11.92 Mn |
| Sep 30, 2023 | -18.27 Mn |
| Jun 30, 2023 | -25.08 Mn |
| Mar 31, 2023 | -21.17 Mn |
| Dec 31, 2022 | -38.02 Mn |
| Sep 30, 2022 | -18.02 Mn |
| Jun 30, 2022 | -23.82 Mn |
| Mar 31, 2022 | -16.77 Mn |
| Dec 31, 2021 | -13.48 Mn |
| Sep 30, 2021 | -24.37 Mn |
| Jun 30, 2021 | -31.13 Mn |
| Mar 31, 2021 | -29.63 Mn |
| Dec 31, 2020 | -40.16 Mn |
| Sep 30, 2020 | -29.77 Mn |
| Jun 30, 2020 | -47.69 Mn |
| Mar 31, 2020 | -41.22 Mn |
| Sep 30, 2019 | -131.19 Mn |
| Dec 31, 2018 | -55.59 Mn |
| Sep 30, 2018 | -51.14 Mn |
| Jun 30, 2016 | -55.79 Mn |
| Dec 31, 2015 | -16.35 Mn |
| Jun 30, 2015 | -16.49 Mn |
| Dec 31, 2014 | -15.10 Mn |
| Jun 30, 2014 | -16.57 Mn |